Thyrotropin releasing hormone (TRH)

DRUG2 trials

Sponsors

UConn Health, Memorial Sloan Kettering Cancer Center

Conditions

Cancer-related FatigueThyroid Cancer

Phase 1

Study of Resistance to Thyroid Hormone After Long-term Exposure in People With Thyroid Cancer

WithdrawnNCT04868045

Memorial Sloan Kettering Cancer CenterThyroid Cancer

Start: 2021-04-27End: 2023-02-15Updated: 2023-02-21

Phase 2

Evaluation of Synthetic Thyrotropin Releasing Hormone (TRH) as a Treatment for Cancer-related Fatigue

TerminatedNCT00790296

UConn HealthCancer-related Fatigue

Start: 2006-12-31End: 2010-03-31Updated: 2017-12-28